Nie jesteś zalogowany na forum.

#1 2026-03-17 02:00:26

AlfieHorne
Użytkownik
Data rejestracji: 2025-12-17
Liczba postów: 71
WWW

Bald Mike's Weblog

Rituximab, the humanized chimeric anti-CD20 monoclonal antibody, represents a strong device for treating B-cell malignancies and is licensed for the remedy of relapsed or chemorefractory low-grade or follicular non-Hodgkin's lymphoma (NHL). The direct results of rituximab embrace complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the oblique results embody structural adjustments, apoptosis, and sensitization of cancer cells to chemotherapy. In vitro research have made a big contribution to the understanding of those mechanisms of motion and have led to the event of revolutionary and efficient therapy methods to optimize affected person response. The most vital of those methods is the mix of rituximab and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone), which is proving a extremely efficient mixture within the therapy of NHL. Nevertheless, all patients don't reply equally nicely to rituximab, and in vitro research have recognized a doable mechanism of resistance involving the anti-complement inhibitors CD55 and CD59. Neutralizing antibodies to CD55 and CD59 can overcome resistance to rituximab-mediated complement-mediated cytotoxicity in vitro. This paper overviews our understanding of the mechanisms of motion of rituximab and identifies how this data may very well be utilized in a clinical setting to maximise response in each delicate and resistant patients.

my website rituximab biosimilar rheumatoid arthritis [see this website]


my homepage :: rituximab fda label (click the up coming webpage)

Offline

Stopka

Forum oparte na FluxBB